From NAFLD to HCC: Advances in noninvasive diagnosis

Xu, Qinchen; Feng, Maoxiao; Ren, Yidan; Liu, Xiaoyan; Gao, Hongtao; Li, Z P; X, Su; Wang, Qin; Wang, Yunshan

doi:10.1016/j.biopha.2023.115028

Cited by 2 publications

(5 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the sensitivity of ultrasound scanning is moderate, with poorer diagnostic performance in early HCC stages [132]. Many serum biomarkers have been investigated for more accurate diagnosis of NAFLD/MAFLD/MASLD-associated HCC without the need for imaging which have been discussed in detail in other reviews [133,134]. The most common serum biomarkers for HCC diagnosis include AFP, AFP isoform L3 (AFP-L3) and des-carboxyprothrombin (DCP) [133].…”

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

“…Both AFP-L3 and DCP have demonstrated comparable diagnostic accuracy to AFP, with the combined use of AFP with either of the other two biomarkers improving the overall diagnostic performance when compared to each one alone [133,135,136]. The most reliable scoring system for HCC is the GALAD score which incorporates age, sex, AFP, lectin-bound AFP and DCP [134,135]. In a study by Best et al the GALAD score had an excellent diagnostic performance with an AUROC of 0.96, outperforming all three biomarkers (AFP, DCP, AFP-L3) when evaluated alone [135].…”

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

“…In a study by Best et al the GALAD score had an excellent diagnostic performance with an AUROC of 0.96, outperforming all three biomarkers (AFP, DCP, AFP-L3) when evaluated alone [135]. Whilst the GALAD score is the most promising to date, its application is limited to those with advanced HCC, with uncertain value in monitoring early HCC [134,137]. Novel potential biomarkers are currently being investigated, including genetic and epigenetic biomarkers [133,134].…”

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

“…Whilst the GALAD score is the most promising to date, its application is limited to those with advanced HCC, with uncertain value in monitoring early HCC [134,137]. Novel potential biomarkers are currently being investigated, including genetic and epigenetic biomarkers [133,134]. Indeed, genomic research has identified telomerase reverse transcriptase (TERT) promoter mutations as the most common form of HCC alteration [133].…”

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

See 3 more Smart Citations

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Abdelhameed,

Kite,

Lagojda

et al. 2024

Curr Obes Rep

View full text Add to dashboard Cite

Purpose of Review The prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause of liver related morbidity and mortality. Currently, liver biopsy is the gold standard for assessing individuals with steatohepatitis and fibrosis. However, its invasiveness, sampling variability, and impracticality for large-scale screening has driven the search for non-invasive methods for early diagnosis and staging. In this review, we comprehensively summarise the evidence on the diagnostic performance and limitations of existing non-invasive serum biomarkers and scores in the diagnosis and evaluation of steatosis, steatohepatitis, and fibrosis. Recent Findings Several non-invasive serum biomarkers and scores have been developed over the last decade, although none has successfully been able to replace liver biopsy. The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metabolic dysfunction-associated steatotic liver disease (MASLD), has initiated a debate on the interchangeability of these terminologies. Indeed, there is a need for more research on the variability of the performance of non-invasive serum biomarkers and scores across the diagnostic entities of NAFLD, MAFLD and MASLD. Summary There remains a significant need for finding valid and reliable non-invasive methods for early diagnosis and assessment of steatohepatitis and fibrosis to facilitate prompt risk stratification and management to prevent disease progression and complications. Further exploration of the landscape of MASLD under the newly defined disease subtypes is warranted, with the need for more robust evidence to support the use of commonly used serum scores against the new MASLD criteria and validation of previously developed scores.

show abstract

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

Section: Novel Biomarkers and Combination Scoresmentioning

confidence: 99%

See 2 more Smart Citations

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Abdelhameed,

Kite,

Lagojda

et al. 2024

Curr Obes Rep

View full text Add to dashboard Cite

show abstract

“…At the individual level, hepatic steatosis can lead to a range of adverse health outcomes, including impaired liver function, inflammation, fibrosis, cirrhosis, and an increased risk of hepatocellular carcinoma [6]. These complications can significantly affect an individual's quality of life and may necessitate medical interventions such as lifestyle modifications, pharmacological treatments, and, in more advanced cases, liver transplantation [6][7][8]. Therefore, understanding the progression of hepatic steatosis is essential for identifying individuals at higher risk of disease advancement and tailoring appropriate management strategies to mitigate these risks.…”

Section: Understanding the Progression Of Hepatic Steatosis And The I...mentioning

confidence: 99%

Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis

Tudor,

Gheorman,

Simeanu

et al. 2024

Metabolites

View full text Add to dashboard Cite

The utilization of evolutive models and algorithms for predicting the evolution of hepatic steatosis holds immense potential benefits. These computational approaches enable the analysis of complex datasets, capturing temporal dynamics and providing personalized prognostic insights. By optimizing intervention planning and identifying critical transition points, they promise to revolutionize our approach to understanding and managing hepatic steatosis progression, ultimately leading to enhanced patient care and outcomes in clinical settings. This paradigm shift towards a more dynamic, personalized, and comprehensive approach to hepatic steatosis progression signifies a significant advancement in healthcare. The application of evolutive models and algorithms allows for a nuanced characterization of disease trajectories, facilitating tailored interventions and optimizing clinical decision-making. Furthermore, these computational tools offer a framework for integrating diverse data sources, creating a more holistic understanding of hepatic steatosis progression. In summary, the potential benefits encompass the ability to analyze complex datasets, capture temporal dynamics, provide personalized prognostic insights, optimize intervention planning, identify critical transition points, and integrate diverse data sources. The application of evolutive models and algorithms has the potential to revolutionize our understanding and management of hepatic steatosis, ultimately leading to improved patient outcomes in clinical settings.

show abstract

From NAFLD to HCC: Advances in noninvasive diagnosis

Cited by 2 publications

References 161 publications

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis

Contact Info

Product

Resources

About